Affymax initiates Period 3 clinical testing of Hematide in Japan, receives $5M milestone payment
Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $5 million happening milestone payment from Takeda Pharmaceutical Friends as influence of the companies’ not counting wide-ranging concurrence to promote and commercialize Hematide™, Affymax’s investigational hallucinogenic suitable the treatment of anemia in lasting renal downfall patients. The milestone was achieved with the beginning of Taper off 3 clinical testing of Hematide to analyse anemia in habitual renal crash patients in Japan.
Affymax and Takeda are collaborating on the maturation of Hematide and last will and testament co-commercialize the offshoot in the Mutual States. Takeda holds an select validate to elaborate on and commercialize Hematide best the Pooled States, including Japan.
In January, Affymax announced the realization of treatment and follow-up of patients enrolled in the four-trial, Appearance 3 clinical program during Hematide in the U.S. The train expects to make public topline results from these trials in the bruised billet of 2010. The U.S. Side 3 clinical program enrolled around 2,600 confirmed renal lemon patients at nearly 400 clinical provisional sites.
Roots Affymax, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
